DNA sequences encoding full-length outer surface protein (Osp) A were amplified from four joint fluid samples over 4.5 months from a patient with chronic Lyme arthritis, with a variant from wild type only found in sample 3. Rather than a mutation in vivo, these findings suggested a mixed infection in which Borrelia containing the wild-type and mutant ospA were waxing and waning in the patient's joint. If so, we reasoned that the mutant should be present in the community. We therefore took the novel epitope resulting from the mutation, expressed as a fusion protein in Escherichia coli, and performed Western blots on 80 high-titred stored sera; however, all except that of our index patient were negative. We then collected 36 stored sera from patients with Lyme disease residing within 10 miles of where the index patient had lived. An additional two sera from this circumscribed area were positive (P = 0.038). These findings show that results from single samples can be misleading, and suggest that the OspAs expressed in force late in Lyme arthritis are the same ones introduced initially into the host. Moreover, they allow a speculative mechanism for disease persistence not previously considered, in which antigenically distinct B. burgdorferi variant proteins present themselves serially to the immune system.
Lyme disease is caused by infection with the tickover 4.5 months, and expressed OspA as a glutathione transferase (GT ) fusion protein in Escherichia coli [5] . transmitted spirochete Borrelia burgdorferi and is charOspA monoclonal antibodies that passively protected acterized by a transient rash [erythema (chronicum) mice from infection did not bind the expressed OspA migrans] and sometimes by subsequent neurological, from the third of those samples, due to a deletion in cardiac, or joint involvement [1] . Most patients are ospA that resulted in a frame shift and premature stop readily cured at all stages by antibiotic therapy, but codon near the carboxyl terminus, where protective some individuals have persistent or recurrent disease [1] .
antibodies bind. Repeated amplification and sequencing, Passive immunization with murine or human antibodas well as the presence of patient antibodies to the ies to outer surface protein A (OspA) can protect mice expressed novel epitope, showed that this was not an against B. burgdorferi [2], and active immunization with artefact of the procedures employed. recombinant human OspA induces protective immunity
Had we amplified only the third sample in that study, [3, 4], but OspA antibodies elicited during natural we might have concluded that the loss of protective infection in mice or men are unable to clear the spiroepitope(s) due to in vivo mutation may be one reason chaete from the infected host. To examine antibody that the spirochaete persists. However, the amplification binding by OspA during the course of human infection, of wild-type ospA from the first two samples from that in earlier work [5] we amplified the operon encoding patient, who already had had chronic arthritis for several full-length ospA and ospB from synovial fluids of a months, makes this explanation less compelling. patient with chronic Lyme arthritis-the first such recovMoreover, the amplification of ospA without this deleeries from human material-at four separate time points tion from a subsequent (fourth) sample of synovial fluid demonstrates that other mechanisms of persistence must be in play [5] .
occasion to harbour more than one strain of B. burgdorsimultaneously for adsorbed and the corresponding unadsorbed patient sera. feri in a single specimen [6] [7] [8] [9] , was a young woman with a history of erythema novel peptide was further analysed after that serum had migrans and an influenza-like syndrome, followed 10 been pre-adsorbed against GT alone, to rule out reactivmonths later by a swollen left knee, sore right temporoity with GT rather than with the novel epitope. To our mandibular joint, and high-titred specific IgG antibody initial surprise, all these sera except that of the index against B. burgdorferi in her serum. Over several subpatient were negative, or became so after adsorption of sequent months, joint involvement persisted despite GT. We then considered the possibility that this particucourses of oral and intravenous antibiotics, making lar variant may be rare and limited to ticks from a available serial samples of synovial fluid for testing. One rather restricted area, and noted that only three of the month after the fourth sample, an arthroscopic synovec-80 sera came from patients who resided within 10 miles tomy produced an apparent cure; the patient is currently of the geographic location where the index patient was more than a decade without recurrence. Our knowledge living when she developed Lyme disease. We therefore of other individuals whose sera was stored at Yale sought from colleagues, stored positive sera from University or obtained from colleagues elsewhere, was patients with Lyme disease who lived within that radius. limited to test results and to towns of habitation.
From 36 such sera, we found two additional samples Immunoblots using the novel peptide that reacted against the novel epitope, both of them from patients who resided within 8 miles of the index The peptide corresponding to amino acids 232-254 of the OspA frame shift mutation region was generated patient (Figs 1 and 2) . ( This region is highly endemic for Lyme disease, but because data on these two patients and expressed in E. coli as a fusion protein with GT as described previously [5] . Lysates (1.5 mg) of E. coli were limited to test results and to towns of habitation, we cannot say for certain in what town they were bitten.) expressing recombinant GT and GT-peptide were resolved by sodium dodecyl sulphate-polyacrylamide
The likelihood of this being a chance cluster is low (0 of 77 vs 3 of 40; P = 0.038). gel electrophoresis (SDS-PAGE ) in a 15% polyacrylamide gel, transferred to nitrocellulose, and strips were probed with patient sera at a dilution of 1:500 in Discussion phosphate-buffered saline (PBS) with 1% bovine serum albumin (BSA) for >3 h. Nitrocellulose strips were
We discovered Lyme disease because of geographic clustering of patients with arthritis in the region of washed with Tris-buffered saline, pH 8, containing 0.2% Tween 20 ( TBST ), incubated with alkaline phosphataseLyme, Connecticut [10] . Now geographic clustering, this time of a Borrelia mutant, may be directing us conjugated goat anti-human IgG (Promega, Madison, WI, USA), washed in TBST, and developed with further in understanding the workings of this illness.
Here we make three points about this finding. 5-bromo-4-chloro-3-indoyl phosphate and nitroblue tetrazolium phosphatase substrate ( Kirkegaard and
In vivo constancy of OspA variants over time Perry Laboratories, Gaithersburg, MD, USA) as described previously [5] .
The expression of OspA declines rapidly in both the engorged tick and in the mammalian host [11, 12] , and For purification prior to testing (to suppress background binding to GT alone) selected patient sera were the early development of antibody to OspA is modest and transient; the return of OspA antibody production pre-adsorbed against recombinant GT bound to nitrocellulose. For pre-adsorption, 1 × 0.5 inch strips of in force is a late finding, especially prominent with the development of Lyme arthritis [13] [14] [15] . The implication nitrocellulose were incubated with 36 mg of GT (360 ng/ml in PBS), air dried, and then each patient from the geographical data is that at least these two antigenically distinct OspAs, if they are indeed being serum (at a 1:500 dilution) was incubated four times with GT strips (overnight at 4°C and three times for 1 h re-expressed and are driving the antibody response to them in late disease, are isogenic with those initially at room temperature). Western blots were carried out F. 1. Sera of patients with Lyme disease tested for the novel peptide, displayed by patients' home towns. Unlike that of the index patient (+), none of 80 high-titred sera from patients with Lyme disease reacted against the novel peptide. The 59 sera from patients with addresses in Connecticut are shown ($). In contrast, of 36 additional sera from patients who lived within 10 miles of the index patient (#), two were positive (6) . The likelihood of this being a chance cluster is low (P = 0.038).
introduced into the host. This finding is in keeping with
A possible mechanism for chronic disease work in C3H mice in which B. burgdorferi strains This is the first recovery, from the joint of a patient recovered after 1 yr of infection were isogenic with with Lyme arthritis, of DNA coding for more than a respect to their parent clone [16 ] .
single antigenically distinct version of a given B. burgdorferi protein. Although OspA may not be the key protein Amplicons from single patient specimens may be in disease persistence, it may serve here as a model for misleading those that are. It has been suggested that ticks and small This point is partially discussed in the Introduction. We mammals, thriving in terminal moraines in the Northern would further emphasize that the OspA wild type and Hemisphere, may have been passing Borrelia (and other the frame-shifted mutant may have been present to some micro-organisms) back and forth for millennia [18] , extent in all the synovial fluid samples. Because polyproviding time for random mutation of an order not merase chain reaction (PCR) amplification proceeds by comparable to the spirochaete's brief, dead-end sojourn geometric progression, the sequence that gets a head in a human host. Borrelia burgdorferi is thought to find start, often because of its relative abundance or privileged sites in the mammalian host, where it is annealing efficiency, will quickly leave other sequences invisible to the immune system [1]. One such site may behind. Thus, other OspA mutants than the one be inside cells [19] [20] [21] [22] . Indeed, several intracellular expressed in sample 3 may also have been present in spirochetes were recently described in synovial tissue some samples, as well as variants of coding sequences from a patient with chronic Lyme arthritis [23]. Lyme not specifically sought here. Indeed, the recent establishdisease is thought to result from the host response to a ment of the genomic sequence of the Lyme spirochaete bacterium that is antigenically powerful but otherwise reveals a large array of duplicated lipoprotein genes, rather unaggressive [1] . In this formulation, in order for the inflammation to persist, Borrelia, or antigenic comunique to Borrelia spp. and of unknown function [17] . Fig. 1 . Note that only GT alone was suppressed after GT adsorption (B: 3a, 4a, 5a); the recombinant peptide (B: 3b, 4b, 5b) retained specific activity. In contrast, in lane 1, probed with control serum, and in lane 2, probed with a representative high-titred serum from a patient with Lyme disease, both GT alone (1a, 2a) and the recombinant protein (1b, 2b) were suppressed after GT adsorption, indicating that the reactivity to both targets was due to GT. In lane 6, both antigens were stained with Coomassie brilliant blue to show that comparable amounts of protein were loaded per lane.
ponents of them, must periodically expose themselves Connecticut Children's Medical Center for additional sera and to Dr Alvan Feinstein for statistical analysis. to host defences. In the case of the mutant OspA, the loss of epitopes where protective antibodies bind [5] This work was supported in part by grants from the USPHS (AI-30548, AI43558, AR-10493), the Mathers cannot by itself explain persistence of disease, because the patient did not clear wild-type OspA, either.
and Eshe Foundations, the Arthritis Foundation, and the Community Foundation of Greater New Haven. However, one may speculate that in some patients with Lyme disease, the immune system must deal successively with mixed B. burgdorferi variants of the critical proteins References involved in disease persistence, or with their antigenic products. These variants may leave privileged sites in 
